Metoject

Methotrexate, the active ingredient in Metoject, is an antimetabolite presented as an injectable solution for intramuscular, intravenous, or subcutaneous use. It is employed in the management of rheumatoid arthritis, psoriasis, and selected malignancies such as acute lymphoblastic leukemia, non‑Hodgkin lymphoma, and breast cancer in both adult and pediatric patients.

GNH USA supplies Metoject as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, and pharmacies worldwide, providing reliable sourcing, regulatory support, and cold‑chain logistics for this injectable chemotherapy and immunosuppressant agent.

Methotrexate is an antimetabolite used to modulate immune activity and inhibit cancer cell proliferation.

- Rheumatoid arthritis: reduces joint inflammation and slows disease progression. - Psoriasis: diminishes skin lesions and plaque formation. - Acute lymphoblastic leukemia: interferes with malignant cell replication. - Non‑Hodgkin lymphoma: impedes tumor growth. - Breast cancer: enhances the effectiveness of combination chemotherapy. - Ectopic pregnancy: terminates trophoblastic tissue when surgery is not feasible.

Methotrexate may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea or vomiting. - Fatigue or malaise. - Mouth sores (stomatitis). - Mild elevation of liver enzymes. - Temporary hair thinning.

Serious or Rare Side Effects: - Severe liver toxicity or fibrosis. - Pulmonary fibrosis or interstitial pneumonitis. - Significant bone marrow suppression leading to infection or bleeding. - Acute renal failure. - Anaphylactic or severe hypersensitivity reactions.

Prior to initiating therapy, several safety measures should be observed.

- Monitor blood counts: perform regular CBC to detect cytopenias. - Assess liver function: check transaminases before and during treatment. - Avoid use in pregnancy: methotrexate is contraindicated and requires effective contraception. - Counsel on contraception: both male and female patients must use reliable methods. - Adjust dose in renal impairment: reduce dosage or increase monitoring as needed. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Methotrexate can interact with several medicines, altering its efficacy or toxicity.

Major Interactions (Avoid): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): increase risk of renal toxicity. - Proton pump inhibitors (e.g., omeprazole): may raise methotrexate plasma levels. - Trimethoprim‑sulfamethoxazole: potentiates bone marrow suppression.

Moderate Interactions (Monitor Closely): - Azathioprine or other immunosuppressants: additive myelosuppression. - Live vaccines: risk of infection due to immunosuppression.